Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an announcement.
Chimeric Therapeutics has made significant progress in its CHM CDH17 program, advancing to dose level 2 in its Phase 1/2 study for gastroenteropancreatic neuroendocrine tumors. The company received FDA Fast Track Designation and activated a fourth US clinical site, demonstrating its commitment to accelerating clinical pipelines. The ADVENT-AML Phase 1B trial also reported promising early results, and the company successfully raised $16.6 million to support its initiatives. These developments position Chimeric as a key player in the cell therapy industry, potentially impacting stakeholders positively by advancing cancer treatment options.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an Australian company specializing in cell therapy. It focuses on developing advanced treatments for cancer, particularly through its innovative CAR-T cell therapy programs.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.75M
See more data about CHM stock on TipRanks’ Stock Analysis page.